Cargando…

Exploring novel genetic and hematological predictors of response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer

Introduction: The standard treatment for locally advanced rectal cancer (LARC) is neoadjuvant chemoradiotherapy (nCRT). To select patients who would benefit the most from nCRT, there is a need for predictive biomarkers. The aim of this study was to evaluate the role of clinical, pathological, radiol...

Descripción completa

Detalles Bibliográficos
Autores principales: Marinkovic, Mladen, Stojanovic-Rundic, Suzana, Stanojevic, Aleksandra, Ostojic, Marija, Gavrilovic, Dusica, Jankovic, Radmila, Maksimovic, Natasa, Stroggilos, Rafael, Zoidakis, Jerome, Castellví-Bel, Sergi, Fijneman, Remond J. A., Cavic, Milena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10501402/
https://www.ncbi.nlm.nih.gov/pubmed/37719698
http://dx.doi.org/10.3389/fgene.2023.1245594
_version_ 1785106109963436032
author Marinkovic, Mladen
Stojanovic-Rundic, Suzana
Stanojevic, Aleksandra
Ostojic, Marija
Gavrilovic, Dusica
Jankovic, Radmila
Maksimovic, Natasa
Stroggilos, Rafael
Zoidakis, Jerome
Castellví-Bel, Sergi
Fijneman, Remond J. A.
Cavic, Milena
author_facet Marinkovic, Mladen
Stojanovic-Rundic, Suzana
Stanojevic, Aleksandra
Ostojic, Marija
Gavrilovic, Dusica
Jankovic, Radmila
Maksimovic, Natasa
Stroggilos, Rafael
Zoidakis, Jerome
Castellví-Bel, Sergi
Fijneman, Remond J. A.
Cavic, Milena
author_sort Marinkovic, Mladen
collection PubMed
description Introduction: The standard treatment for locally advanced rectal cancer (LARC) is neoadjuvant chemoradiotherapy (nCRT). To select patients who would benefit the most from nCRT, there is a need for predictive biomarkers. The aim of this study was to evaluate the role of clinical, pathological, radiological, inflammation-related genetic, and hematological parameters in the prediction of post-nCRT response. Materials and methods: In silico analysis of published transcriptomics datasets was conducted to identify candidate genes, whose expression will be measured using quantitative Real Time PCR (qRT-PCR) in pretreatment formaline-fixed paraffin-embedded (FFPE) samples. In this study, 75 patients with LARC were prospectively included between June 2020—January 2022. Patients were assessed for tumor response in week 8 post-nCRT with pelvic MRI scan and rigid proctoscopy. For patients with a clinical complete response (cCR) and initially distant located tumor no immediate surgery was suggested (“watch and wait” approach). The response after surgery was assessed using histopathological tumor regression grading (TRG) categories from postoperative specimens by Mandard. Responders (R) were defined as patients with cCR without operative treatment, and those with TRG 1 and TRG 2 postoperative categories. Non-responders (NR) were patients classified as TRG 3-5. Results: Responders group comprised 35 patients (46.6%) and NR group 53.4% of patients. Analysis of published transcriptomics data identified genes that could predict response to treatment and their significance was assessed in our cohort by qRT-PCR. When comparison was made in the subgroup of patients who were operated (TRG1 vs. TRG4), the expression of IDO1 was significantly deregulated (p < 0.05). Among hematological parameters between R and NR a significant difference in the response was detected for neutrophil-to-monocyte ratio (NMR), initial basophil, eosinophil and monocyte counts (p < 0.01). According to MRI findings, non-responders more often presented with extramural vascular invasion (p < 0.05). Conclusion: Based on logistic regression model, factors associated with favorable response to nCRT were tumor morphology and hematological parameters which can be easily and routinely derived from initial laboratory results (NMR, eosinophil, basophil and monocyte counts) in a minimally invasive manner. Using various metrics, an aggregated score of the initial eosinophil, basophil, and monocyte counts demonstrated the best predictive performance.
format Online
Article
Text
id pubmed-10501402
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-105014022023-09-15 Exploring novel genetic and hematological predictors of response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer Marinkovic, Mladen Stojanovic-Rundic, Suzana Stanojevic, Aleksandra Ostojic, Marija Gavrilovic, Dusica Jankovic, Radmila Maksimovic, Natasa Stroggilos, Rafael Zoidakis, Jerome Castellví-Bel, Sergi Fijneman, Remond J. A. Cavic, Milena Front Genet Genetics Introduction: The standard treatment for locally advanced rectal cancer (LARC) is neoadjuvant chemoradiotherapy (nCRT). To select patients who would benefit the most from nCRT, there is a need for predictive biomarkers. The aim of this study was to evaluate the role of clinical, pathological, radiological, inflammation-related genetic, and hematological parameters in the prediction of post-nCRT response. Materials and methods: In silico analysis of published transcriptomics datasets was conducted to identify candidate genes, whose expression will be measured using quantitative Real Time PCR (qRT-PCR) in pretreatment formaline-fixed paraffin-embedded (FFPE) samples. In this study, 75 patients with LARC were prospectively included between June 2020—January 2022. Patients were assessed for tumor response in week 8 post-nCRT with pelvic MRI scan and rigid proctoscopy. For patients with a clinical complete response (cCR) and initially distant located tumor no immediate surgery was suggested (“watch and wait” approach). The response after surgery was assessed using histopathological tumor regression grading (TRG) categories from postoperative specimens by Mandard. Responders (R) were defined as patients with cCR without operative treatment, and those with TRG 1 and TRG 2 postoperative categories. Non-responders (NR) were patients classified as TRG 3-5. Results: Responders group comprised 35 patients (46.6%) and NR group 53.4% of patients. Analysis of published transcriptomics data identified genes that could predict response to treatment and their significance was assessed in our cohort by qRT-PCR. When comparison was made in the subgroup of patients who were operated (TRG1 vs. TRG4), the expression of IDO1 was significantly deregulated (p < 0.05). Among hematological parameters between R and NR a significant difference in the response was detected for neutrophil-to-monocyte ratio (NMR), initial basophil, eosinophil and monocyte counts (p < 0.01). According to MRI findings, non-responders more often presented with extramural vascular invasion (p < 0.05). Conclusion: Based on logistic regression model, factors associated with favorable response to nCRT were tumor morphology and hematological parameters which can be easily and routinely derived from initial laboratory results (NMR, eosinophil, basophil and monocyte counts) in a minimally invasive manner. Using various metrics, an aggregated score of the initial eosinophil, basophil, and monocyte counts demonstrated the best predictive performance. Frontiers Media S.A. 2023-08-31 /pmc/articles/PMC10501402/ /pubmed/37719698 http://dx.doi.org/10.3389/fgene.2023.1245594 Text en Copyright © 2023 Marinkovic, Stojanovic-Rundic, Stanojevic, Ostojic, Gavrilovic, Jankovic, Maksimovic, Stroggilos, Zoidakis, Castellví-Bel, Fijneman and Cavic. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Genetics
Marinkovic, Mladen
Stojanovic-Rundic, Suzana
Stanojevic, Aleksandra
Ostojic, Marija
Gavrilovic, Dusica
Jankovic, Radmila
Maksimovic, Natasa
Stroggilos, Rafael
Zoidakis, Jerome
Castellví-Bel, Sergi
Fijneman, Remond J. A.
Cavic, Milena
Exploring novel genetic and hematological predictors of response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer
title Exploring novel genetic and hematological predictors of response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer
title_full Exploring novel genetic and hematological predictors of response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer
title_fullStr Exploring novel genetic and hematological predictors of response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer
title_full_unstemmed Exploring novel genetic and hematological predictors of response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer
title_short Exploring novel genetic and hematological predictors of response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer
title_sort exploring novel genetic and hematological predictors of response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer
topic Genetics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10501402/
https://www.ncbi.nlm.nih.gov/pubmed/37719698
http://dx.doi.org/10.3389/fgene.2023.1245594
work_keys_str_mv AT marinkovicmladen exploringnovelgeneticandhematologicalpredictorsofresponsetoneoadjuvantchemoradiotherapyinlocallyadvancedrectalcancer
AT stojanovicrundicsuzana exploringnovelgeneticandhematologicalpredictorsofresponsetoneoadjuvantchemoradiotherapyinlocallyadvancedrectalcancer
AT stanojevicaleksandra exploringnovelgeneticandhematologicalpredictorsofresponsetoneoadjuvantchemoradiotherapyinlocallyadvancedrectalcancer
AT ostojicmarija exploringnovelgeneticandhematologicalpredictorsofresponsetoneoadjuvantchemoradiotherapyinlocallyadvancedrectalcancer
AT gavrilovicdusica exploringnovelgeneticandhematologicalpredictorsofresponsetoneoadjuvantchemoradiotherapyinlocallyadvancedrectalcancer
AT jankovicradmila exploringnovelgeneticandhematologicalpredictorsofresponsetoneoadjuvantchemoradiotherapyinlocallyadvancedrectalcancer
AT maksimovicnatasa exploringnovelgeneticandhematologicalpredictorsofresponsetoneoadjuvantchemoradiotherapyinlocallyadvancedrectalcancer
AT stroggilosrafael exploringnovelgeneticandhematologicalpredictorsofresponsetoneoadjuvantchemoradiotherapyinlocallyadvancedrectalcancer
AT zoidakisjerome exploringnovelgeneticandhematologicalpredictorsofresponsetoneoadjuvantchemoradiotherapyinlocallyadvancedrectalcancer
AT castellvibelsergi exploringnovelgeneticandhematologicalpredictorsofresponsetoneoadjuvantchemoradiotherapyinlocallyadvancedrectalcancer
AT fijnemanremondja exploringnovelgeneticandhematologicalpredictorsofresponsetoneoadjuvantchemoradiotherapyinlocallyadvancedrectalcancer
AT cavicmilena exploringnovelgeneticandhematologicalpredictorsofresponsetoneoadjuvantchemoradiotherapyinlocallyadvancedrectalcancer